ArticleNPJ breast cancer2026
Development and internal validation of mammography feature-based prognostic models for distant recurrence-free survival of invasive breast cancer in a screening cohort.
Article in NPJ breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Overdiagnosis in breast cancer screening may be reduced by identifying lesions that, although detected on screening mammograms, are unlikely to progress to poor outcomes and may not require recall. As a proof-of-concept, we evaluated prognostic models for 10-year distant recurrence-free survival (DRFS) using radiomics features from invasive breast cancers (IBCs) presenting as masses on screening mammograms. In a cohort of screened women, 1466 IBC patients with clinical, pathological, and follow-up data were identified through national registries. Using radiomics features, tumor volume, and specific growth rate, proportional hazards models were developed to predict 10-year distant recurrence risk. Models were trained using positive screening mammograms of patients with screen-detected IBC (n = 1063) and diagnostic mammograms of patients with interval cancer (n = 406). Performance was evaluated only in screen-detected IBCs using repeated nested cross-validation. Median follow-up was 5.1 years (10th-90th percentile: 2.1-10.1), with 111 distant recurrences within 10 years. Model performance was moderate (C-index 0.70 [SD 0.01], calibration slope 1.22 [SD 0.13]), with predicted 10-year recurrence risks ranging from 4.9% to 18.0% (10th-90th percentile). The 42 IBCs with the lowest predicted risk had a 10-year recurrence probability of 2.6% (95% CI 0-7.5%), of whom only five received adjuvant systemic therapy. These findings suggest that mammography-based radiomics features may help identify low-risk IBCs and potentially reduce overdiagnosis by reconsidering recall for selected cases.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.